
	Ms. Kathryn E. Falberg, also known as Kate, has been a Consultant to Jazz Pharmaceuticals Public Limited Company since March 9, 2014. Ms. Falberg served as the Chief Financial Officer of Jazz Pharmaceuticals Public Limited Company from 2009 to March 9, 2014 and its Executive Vice President since March 2012 until February 2014. Ms. Falberg serves as the Chief Financial Officer and Senior Vice President of Azur Pharma Limited. She is responsible for Jazz&#39;s accounting, corporate finance, financial planning, investor relations, and treasury functions. She served as Senior Vice President of Jazz Pharmaceuticals Public Limited Company from December 2009 to 2012. She served as Chief Operating Officer and Chief Financial Officer of ARCA biopharma, Inc. since February 24, 2009 until November 30, 2009 and was responsible for its accounting, corporate finance, financial planning, treasury and other corporate functions. Since 2001 until joining ARCA in 2009, she worked as an active investor and consultant to small companies. Ms. Falberg has over 23 years of financial experience with companies of varying sizes across multiple industries. She served as President of Canyon Capital &amp; Consulting, an investment and consulting firm, from 2003 to 2008. She served as Senior Vice President of Finance &amp; Strategy and Corporate Development and Chief Financial Officer of Amgen Inc., from 1998 to July 2001. She joined Amgen in 1995 as Treasurer, and advanced through a series of positions of increasing responsibility including Vice President, Controller and Chief Accounting Officer. Prior to Amgen, Ms. Falberg served as Vice President, Chief Financial Officer, Controller, Chief Accounting Officer and Treasurer of Innovative Micro Technology, Inc. (formerly Applied Magnetics Corporation) from 1984 to 1994. From October 2001 to June 2002, Ms. Falberg was a Consultant of INAMED Corp., a medical device company, and briefly served as its Interim Chief Financial Officer. She serves as a Director at AESS Technology, Inc. She has been an Independent Director of Halozyme Therapeutics, Inc., since May 2007. She has been Director of Medivation, Inc. since February 2013. She served as Director of QLT Inc., from March 25, 2009 to June 5, 2012. She served as a Director of Fresh Del Monte Produce Inc., since December 6, 2002. She served as an Independent Director of Human Genome Sciences Inc., from March 3, 2004 to December 2005. She served as a Director of AMO Manufacturing USA, LLC. She is a Certified Public Accountant. Ms. Falberg holds an MBA and a BA in Economics from the University of California, Los Angeles.
